Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has earned a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, one has given a buy rating and five have issued a strong buy rating on the company.
Several brokerages have commented on GLX. Citigroup upgraded shares of Bradmer Pharmaceuticals to a “hold” rating in a report on Tuesday, February 24th. ATB Cormark Capital Markets cut shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a report on Thursday, February 5th. Finally, Citizens Jmp raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, December 9th.
View Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Further Reading
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
